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A B S T R A C T
Hypothyroidism is a chronic and debilitating disease that is estimated to aﬀect 3% of the general population.
Clinical experience has highlighted the synergistic value of combining triiodothyronine (T3) and thyroxine (T4)
for persistent or recurrent symptoms. However, thus far a platform that enables the simultaneous and in-
dependent dosing of more than one drug for oral administration has not been developed. Thermal inkjet (TIJ) 2D
printing is a potential solution to enable the dual deposition of T3 and T4 onto orodispersible ﬁlms (ODFs) for
therapy personalisation. In this study, a two-cartridge TIJ printer was modiﬁed such that it could print separate
solutions of T3 and T4. Dose adjustments were achieved by printing solutions adjacent to each other, enabling
therapeutic T3 (15–50 μg) and T4 dosages (60–180 μg) to be successfully printed. Excellent linearity was ob-
served between the theoretical and measured dose for both T3 and T4 (R2= 0.982 and 0.985, respectively) by
changing the length of the print objective (Y-value). Rapid disintegration of the ODFs was achieved (< 45 s). As
such, this study for the ﬁrst time demonstrates the ability to produce personalised dose combinations by TIJ
printing T3 and T4 onto the same substrate for oral administration.
1. Introduction
Hypothyroidism is the most common thyroid ailment, estimated to
aﬀect around 3% of the general population (Vaidya and Pearce, 2008).
This condition is characterised by a deﬁciency of the thyroid hormones,
triiodothyronine (T3) and thyroxine (T4), which normally aid in con-
trolling a number of essential physiological processes, including brain
development, skeletal maturation, oxygen consumption, heat produc-
tion and heart contractility (Kirsten, 2000). As such, hypothyroid states
often create debilitating symptoms for patients, such as chronic fatigue,
weight gain and cold intolerance, making the regulation and main-
tenance of T3 and T4 levels of critical importance.
The ‘active’ thyroid hormone (T3) mediates the vast majority of
normal physiological processes and is predominantly (∼80%) derived
from the metabolism of T4 by iodothyronine deiodinases (Wartofsky,
2013). Despite this, the mainstay of hypothyroid treatment involves
levothyroxine (T4) only, with the assumption that suﬃcient T3 is re-
generated from T4 in the peripheral tissues (Celi et al., 2011; Collier
et al., 2011; Saravanan et al., 2005). However, persistent or recurrent
hypothyroidism has been reported in approximately 10–20% of patients
taking T4 monotherapy (Appelhof et al., 2005; Walsh, 2002; Wartofsky,
2013; Wiersinga, 2009). These patients complain of feeling unwell
despite normal thyroid function tests, raising doubts about the deiodi-
nation of T3 from circulating T4 (Appelhof et al., 2005; Biondi and
Wartofsky, 2012; Wartofsky, 2013). As such, individualized combina-
tion T3 and T4 therapy may be required to represent endogenous hor-
monal rhythms in a more physiological manner.
The value of combining T3 and T4 in hypothyroid patients has been
widely researched and as the clinical condition of the patient evolves,
frequent dose changes are common (Bunevičius et al., 1999; Escobar-
Morreale et al., 2005; Mortoglou, 2004). It is apparent that there is a
clinical need for individualised combination T3 and T4 therapies within
certain patient populations. Current tablet forms of T3 and T4 contain
synthetic derivatives of the naturally occurring hormones (liothyronine
and levothyroxine, respectively) and exist in separate dosage forms of a
limited number of discrete strengths (e.g. levothyroxine strengths:
25 µg, 50 µg and 100 µg); this often requires patients to take more than
one tablet strength and/or to split tablets to achieve their target dose
(BNF, 2017). These inherently complex dosage regimes can cause pa-
tient confusion, dose variation and hence medication errors (Shah et al.,
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2010; Trenﬁeld et al., 2018a).
As such, there is a major clinical need for the development of a
novel platform that is capable of simultaneously and independently
dosing more than one drug to create personalised dose combinations of
T3 and T4 therapy. One technique that oﬀers great potential is thermal
inkjet (TIJ) printing, a form of two-dimensional (2D) printing. This
process involves a drug being dissolved in a liquid carrier to create a
‘drug ink’, which is contained within a cartridge attached to a print
head nozzle. A current is then pulsed through a resistive element in the
print head, causing an internal temperature rise, followed by vapor-
isation, nucleation and expansion of a bubble; this produces the ne-
cessary energy required to eject a small droplet (2–180 µL) onto a solid
substrate (Buanz et al., 2011; Meléndez et al., 2008).
Due to the capability for the precise spatial control of drug de-
position, TIJ printing has received increasing attention in pharmaceu-
ticals. Favourably, this technology is well suited to the ﬁeld of perso-
nalised medicines by depositing precise dosages of highly potent and/or
narrow therapeutic index drugs onto edible substrates, such as oro-
dispersible ﬁlms (ODFs) (Scoutaris et al., 2011; Vuddanda et al., 2018).
A major driver for printing technologies lie in the possibility of de-
positing separate drugs as a single formulation to produce dose com-
binations. Such advancements have been made with 3D printing,
whereby tablets containing multiple drugs (termed ‘polypills’) have
been printed (Alhnan et al., 2016; Awad et al., 2018a,b; Goyanes et al.,
2015; Khaled et al., 2015a,b; Maroni et al., 2017; Trenﬁeld et al.,
2018a,b). Despite a number of reviews highlighting the potential for
inkjet printing to produce drug combinations (Alomari et al., 2015;
Daly et al., 2015; Preis et al., 2015; Scarpa et al., 2017; Scoutaris et al.,
2011), to date, limited research has explored this concept for oral ad-
ministration. Thus far, studies have mainly focussed on depositing
single drugs onto separate substrates (Buanz et al., 2011; Edinger et al.,
2018; Genina et al., 2013a,b; Kollamaram et al., 2018; Montenegro-
Nicolini et al., 2018; Planchette et al., 2016; Sandler et al., 2011; Vakili
et al., 2017), which is likely due to the unsuitability of current un-
modiﬁed printers to deposit more than one drug in the same print pass.
As such, this study describes the modiﬁcation of a commercial TIJ
printing system to produce customised ODFs containing dose combi-
nations of T3 and T4. The printer used both the black and colour car-
tridges (each containing either T3 or T4 ‘ink’) and dose modiﬁcation was
performed by printing two distinct colours adjacent to each other. The
resulting ODFs were characterised for morphology, disintegration,
solid-state properties and drug content.
2. Method and materials
2.1. Materials
Levothyroxine sodium (T4,> 98.4%, Kemprotec Ltd, UK); liothyr-
onine sodium (T3,> 95%, Sigma Aldrich, UK); sodium hydroxide
(NaOH, 98%, Fischer Scientiﬁc, UK); acetonitrile (ACN, 99.9%, Fischer
Scientiﬁc, UK); sodium acetate (99%, Sigma Aldrich, UK); hydro-
xypropyl methylcellulose (HPMC 6cp, Pharmacoat 606, Shin-Etsu,
Japan); propylene glycol (PG, 99%, Sigma Aldrich, UK); ethanol (ana-
lytical grade, Fischer Scientiﬁc, UK); dimethyl sulfoxide (DMSO, Fischer
Scientiﬁc, UK). The water used in all experiments was ultrapure water.
2.2. Substrate preparation
The substrate ﬁlm gel was composed of HPMC (70% w/w) and
glycerol (30% w/w). Glycerol (3% w/v) was dissolved in water at room
temperature, followed by gradual addition of HPMC (20% w/v) under
continuous stirring at room temperature. The resulting viscous solution
(10 g) was stirred for 4 h until a homogenous gel was formed. The gel
was left to stand for 2 h to eliminate any air bubbles trapped.
Substrate ﬁlms were cast on a ﬂuoropolymer coated polyester sheet
using an automated ﬁlm applicator (Coatmaster 510, Erichsen, Sweden)
equipped with an adjustable coating blade. A ﬁxed wet ﬁlm thickness
(1000 µm) and casting speed (5mm/s) were used. The cast ﬁlms were
dried in an oven for 40min at 60 °C (Binder, Sweden), followed by
storage in a desiccator (23 °C/40% relative humidity; RH). The re-
sulting ﬁlms were used as substrates for printing.
2.3. ‘Ink’ preparation
The printing ‘ink’ comprised solutions of levothyroxine sodium and
liothyronine sodium. No viscosity enhancers or surface tension modi-
ﬁers were needed to make the solutions printable by TIJ. T3 or T4
(20mg) was dissolved in a mixture of ethanol:DMSO:PG (45:45:10 v/v)
at room temperature. The resultant solution was used for printing onto
the ﬁlm substrates.
2.4. Printer modiﬁcation
An HP 5940 (Hewlett Packard Inc., USA) thermal inkjet printer was
modiﬁed and used for printing). The printer was modiﬁed such that
rather than the substrate passing through the printer’s rollers during
operation, instead printing was performed on a stage mounted under-
neath the cartridge print head. Printer modiﬁcation involved removing
certain physical parts of the printer to make space for a stationary stage
under the cartridge print head. Key sensors were also identiﬁed, care-
fully isolated and manually activated appropriately to ensure normal
printer functioning.
In the unmodiﬁed printer, two key sensors require activation to start
the printing process: the printer lid sensor and the paper feed sensor.
During the normal printing process, the lid sensor is engaged with a bar
attached to the printer lid and the paper feed sensor is activated by
disengaging a bar which is required for paper to be fed into the printer.
In the modiﬁed printer, the printer lid was removed and printing
was performed onto a stationary substrate without a paper rolling
mechanism. These activations are manually performed by placing a bar
between the lid sensor to mimic a closed printer lid; a requirement for
printing functionality. The paper feed sensor was also manually acti-
vated by removing a bar which is placed between the sensors when the
printer is idle. More information detailing the modiﬁcation details are
reported elsewhere (Vuddanda et al., 2018).
Black (HP 337) and colour (HP 343) cartridges were modiﬁed by
cutting oﬀ the top, draining the ink, and rinsing several times with
deionised water until clear. Cartridges were then rinsed with ethanol
and dried in air. Printing templates were designed and consisted of solid
yellow rectangles (1 cm width) alongside non-overlapping rectangles of
solid black (1 cm width), as shown in Fig. 1. The height of each of these
rectangles determined the dose deposited. The yellow compartment of
Fig. 1. The representation of Y-values to be
printed in order of increasing yellow and
decreasing black linearly. Y=Yellow colour
(T3), B=Black colour (T4). (For inter-
pretation of the references to colour in this
ﬁgure legend, the reader is referred to the
web version of this article.)
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the colour cartridge (reservoir 1) was ﬁlled with T3 solution whilst the
other two compartments were ﬁlled with deionised water, as shown in
Fig. 2. The black cartridge was ﬁlled with the T4 solution.
2.5. Drug content
The printed substrates were carefully cut using scissors without
touching the printed areas. Samples (1 cm2) were then dissolved in
mixture of ethanol:DMSO:H2O (30:30:40 v/v). Drug concentrations
were determined using high performance liquid chromatography
(HPLC) using the method described elsewhere (Samanidou et al.,
2000). An ODS-3, 150×4.0mm, 5mm analytical column was used
with a mixture of methanol and 2% acetic acid, at a ratio of 65:35 v/v
with a ﬂow rate of 1mL/min and injection volume of 20 µL. The de-
tection was performed using a UV–visible detector at 240 nm. The total
run time for each sample was 10min. Method validation was under-
taken by evaluating inter- and intra-day precision, method accuracy,
limit of detection (LOD) and the limit of quantiﬁcation (LOQ).
2.6. Attenuated total reﬂection-Fourier transform infrared spectroscopy
(ATR-FTIR)
ATR-FTIR was performed with a Perkin-Elmer Spectrum 100 FTIR
Spectrometer (PerkinElmer, UK) using the universal diamond ATR at-
tachment. The spectra were collected in the range of 4000–650 cm−1 at
ambient conditions using a minimum number of four scans per sample.
Spectra were analysed with Spectrum Express software (version 6.3.4,
PerkinElmer, UK).
2.7. Thermal analysis
Thermal measurements were made using diﬀerential scanning ca-
lorimetry (DSC) and thermogravimetric analysis (TGA). DSC was per-
formed using a diﬀerential scanning calorimeter (DSC Q1000, TA
Instruments, USA) and each sample (> 5mg) was placed in a herme-
tically-sealed aluminium pan with a pinhole lid. Pure samples of T3 and
T4 were heated up to 300 °C at 10 °C/min. The printed ﬁlms were
subjected to the following heat-cool-heat cycles with a nitrogen purge
gas (50mL/min). Firstly, the sample was heated from 25 °C to 100 °C at
10 °C/min (to remove water content). The sample was then cooled from
100 °C to 0 °C. Finally, the sample was re-heated from 0 °C to 250 °C at
10 °C/min. An empty pan was used as a reference and the instrument
was previously calibrated for temperature and heat capacities using
indium and sapphire. DSC results were analysed using Universal
Analysis software (version 4.5A, TA instruments, USA).
TGA measurements were performed using a Discovery instrument
(TA instruments, USA). Approximately 5–8mg of the ﬁlm was heated
from 25 °C to 150 °C at 10 °C/min using nitrogen as a purge gas (50mL/
min). Data collection and analysis were performed using Universal
Analysis software (version 4.5A, TA instruments, USA).
2.8. Scanning electron microscopy (SEM)
Surface and cross-section morphology of ﬁlms were captured with
an FEI Inspect F50 Scanning Electron Microscope (SEM) (FEI, Hillsboro,
OR, USA). Film cross-sections were immersed in liquid nitrogen; this
fracture by freezing method ensured clean-cut edges and avoided
plastic deformation. These ﬁlms were then aﬃxed on aluminium stubs
by conductive carbon tape, and sputter-coated with gold (approx.
10–12 nm) in a high vacuum evaporator (108 Auto, Cressington
Scientiﬁc Instruments Ltd, UK).
2.9. Film thickness and disintegration
The thickness of the ﬁlms (1 cm2) was measured using a digital
micrometer (Cokraft® Digital Caliper, Sweden) at three points of each
sample and reported as the mean ± standard deviation (SD). The
disintegration times of the ﬁlms were then evaluated by using a mod-
iﬁed Petri dish method (Garsuch and Breitkreutz, 2010). Samples
(1 cm2) were placed in a Petri dish containing 2mL of water and were
shaken at 60 rpm using an orbital shaker water bath at 37 ± 1 °C. The
time until ﬁlm disintegration was recorded.
3. Results and discussion
A standard HP 5940 Deskjet printer was modiﬁed to enable printing
of multi-drug combination ODFs containing liothyronine (T3) and le-
vothyroxine (T4). The printer was modiﬁed such that, rather than the
substrate (paper in the unmodiﬁed printer) passing through the prin-
ter’s rollers during operation, printing was performed on a stage
mounted underneath the cartridge print head. In particular, the prin-
ter’s sensors were identiﬁed and manually activated to begin the
printing process when required. For printing of ODFs, HPMC substrates
were loaded onto the stage mounted underneath the print head and the
sensors that usually detect paper presence were manually activated.
To dispense two medicated liquids onto the HPMC substrate with
high precision and dose ﬂexibility, two cartridges were used: black and
colour. The colour cartridge contains three separate ink chambers; re-
servoir 1 (Fig. 2) was used since this corresponds to the yellow com-
partment in the colour cartridge. Drug deposition was accomplished by
printing rectangles of 1 cm width of solid yellow non-overlapping with
1 cm width rectangles of solid black. The height of each of these rec-
tangles was the main determinant of the dose deposited since the width
was kept constant; the so-called Y-value approach. This is similar to our
previous work with warfarin that involved a single drug as compared
with a combination of drugs here (Vuddanda et al., 2018).
When such a template is printed, the yellow reservoir of the colour
cartridge will dispense a volume of liquid proportional to the height of
the rectangle (assuming a ﬁxed width across rectangles) and then the
black cartridge will dispense on top of the volume deposited by the
yellow reservoir, because the substrate is static. The second and third
reservoirs in the colour cartridge should not be activated using this
template, at least not signiﬁcantly. Generally, empty reservoirs should
not be activated since this will cause a burnout and potential electrical
shorts of the reservoirs aﬀected. Since the electrical connectors are
Fig. 2. Top view of colour inkjet reservoirs (left); print cartridge with sponges
covering reservoirs (right).
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produced as a single circuit in which damage to one part could aﬀect
the connectors to another, deionised water was placed in reservoirs 2
and 3 during the experiment even though they were not used for
printing purposes.
During printing, the height values of the two cartridges and their
reservoir were set so that one increased while the other decreased; this
was to eliminate the potential for cross-contamination between the
cartridges and to show independent control of each for the purpose of
independently dispensing diﬀerent medicines. For T3, the Y-values
(with a width of 1 cm) were varied from 3 to 12 cm at a constant T3 feed
concentration (20mg/mL). The correlation between the Y-values and
dose deposited demonstrated excellent linearity (R2 0.982), high pre-
cision and accuracy (demonstrated by the low SD values reported
(Fig. 3)). For T4, the Y-values (with a width of 1 cm) were varied from 1
to 7 cm at constant initial T4 feed concentration (20mg/mL). The cor-
relation between the Y-values and dose deposited also demonstrated
excellent linearity (R2= 0.985), high precision and accuracy (low SD)
(Fig. 4). Importantly, it was observed that the substrate ﬁlms were
unable to retain their shape when attempting to print with Y-value
lengths above 7 cm in the case of T4 and 12 cm with T3 solutions. This is
likely due to the hydrophilic substrate ﬁlm being unable to absorb the
volume of solution printed.
During TIJ printing, the overall volumes (and hence doses) that can
be dispensed are rather small. As such, this technology is well suited to
drugs with high potency (and so a narrow therapeutic index) (Alomari
et al., 2015). In previous studies drugs, such as salbutamol sulphate and
theophylline, have been printed onto ODF platforms (Buanz et al.,
2011; Sandler et al., 2011). To this end, T3 and T4 were considered to be
ideally suited for printing onto ODFs, as therapeutic doses of le-
vothyroxine range from 50 to 200 μg daily for adults, whereas lio-
thyronine has been reported to fall within 10–20 μg daily (BNF, 2017,
2018). The lower dosing need of T3 has been attributed to its high
potency in exerting its clinical eﬀects and, therefore, higher potential
for toxicity (Biondi and Wartofsky, 2012). This small dose requires
reﬁnement at a much smaller scale than T4, making T3 a good candidate
for use in the smaller colour reservoir, and the larger black cartridge for
T4. Moreover, the optimum dose is determined as a function of the
patient’s clinical response, as well as biochemical test outcomes such as
monitoring of blood thyroid stimulating hormone (TSH) levels
(Bernareggi et al., 2013), warranting the need for personalisation of
dosages.
Despite being highly potent, to achieve deposition of meaningful
therapeutic doses of T3 and T4 onto the ODFs, high concentrations of
the initial feedstock are required in the printer cartridges. In both cases,
concentrations of 20mg/mL were prepared in mixtures of solvents
(mentioned in the methods section) due to the low solubility of both
drugs in water (DrugBank, 2005a,b). Therapeutic dosages of both T3
(approx. 15–50 μg) and T4 (approx. 60–180 μg) were successfully
printed onto ﬁlms. Many studies have reported the preparation of single
drugs onto substrates. Buanz et al. demonstrated this concept, whereby
a highly potent drug (salbutamol sulphate; 40 μg/cm2 per print pass)
was deposited onto an edible potato starch ﬁlm (Buanz et al., 2011).
Furthermore, Sandler et al. printed 78 μg of a narrow therapeutic index
drug, theophylline, suitable for dosing in children aged 2–12 years old
(Sandler et al., 2011). In the case of hypothyroidism, preparation of T4
printed ODFs by piezoelectric inkjet printing technology has also been
reported (Vakili et al., 2017; Wickström et al., 2018).
A major beneﬁt of TIJ printing lies in the possibility of depositing
separate solutions onto a single substrate to produce dose combina-
tions. Wickström et al. used inkjet printing to formulate a ODF dose
combination of Vitamins B1, B2, B3 and B6 (Wickström et al., 2017).
However, in that case, a single multicomponent solution was prepared
and the vitamins were dispensed together from the same solution ac-
cording to their set ratios. As such, using this method, the doses of each
vitamin cannot be independently changed. Thabet et al. also produced
an ODF dose combination by depositing enalapril solutions onto the
surface of solvent-casted ODFs containing hydrochlorothiazide (HCT)
(Thabet et al., 2018). Moreover, Kollamaram et al. reported inkjet
printing two separate drugs (paracetamol and indomethacin), however
this research focussed on printing onto separate substrates (Kollamaram
et al., 2018).
A proposed method for producing ﬂexible dose combinations in-
volves more than one solution being independently dispensed from
separate cartridges. This concept has been demonstrated for the pre-
paration of bioadhesive ﬁlms containing two anticancer agents in-
tended for cervical administration (Varan et al., 2017). Within that
study, doses of the two drugs were escalated by increasing the number
of layers deposited. However, printing several layers through several
printing cycles could lead to deformation of substrate and loss of drug.
To avoid such complications, this current study utilised the Y-value
concept to enable a greater amount of drug to be printed within a single
printing cycle, reducing the risk of deformation whilst increasing dose
accuracy. To the authors’ knowledge, this study here is the ﬁrst to re-
port the development of an orally-disintegrating dose combination
platform using TIJ printing, enabling two chemically-similar molecules
(T3 and T4) to be independently dispensed onto the same substrate for
single administration.
Fig. 3. Amount of T3 printed onto free ﬁlm substrates upon varying Y-values at
constant initial feed concentration (20mg/mL) (n=3).
Fig. 4. Amount of T4 printed onto free ﬁlm substrates upon varying Y-values at
constant initial feed concentration (20mg/mL) (n=3).
Table 1
Disintegration time of ﬁlms (n=3).
Films Disintegration time (s)
T3 printed ﬁlm 43 ± 2
T4 printed ﬁlm 41 ± 1
Placebo ﬁlm 40 ± 1
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Rapid disintegration is considered a highly important characteristic
for the performance of ODFs, with typical disintegration times ranging
from 5 s to 180 s (FDA, 2008). In this study, the placebo substrate, and
T3- and T4-printed ﬁlms containing diﬀerent doses (179 ± 0.6 and
52 ± 0.62 μg) were found to disintegrate within 43 s (Table 1). These
results also indicate that disintegration was not signiﬁcantly aﬀected by
the presence of T3 or T4, with disintegration times being in agreement
with ODFs composed of HPMC reported in literature (Liew et al., 2012).
DSC thermograms of samples are shown in Fig. 5. The sodium salt of
T3 exhibited an endothermic peak at 234.7 °C and sodium salt of T4
exhibited complex endothermic events at 58.8 °C, 84.6 °C and 97.1 °C,
as well as an exothermic peak at 201.4 °C. The melting endotherms of
T3 and T4 conﬁrmed their crystalline state. The characteristic en-
dothermic and exothermic events were not observed in T3 and T4
printed ﬁlms. The slight change in the baseline observed at 145 °C
corresponds with the glass transition temperature (Tg) of the HPMC
polymer. These ﬁndings could be as a result of two reasons: either the
printed drugs are amorphous after printing or the DSC was not sensitive
enough to detect the heat changes due to the low doses of drug (T3:
0.49% w/w and T4: 1.69% w/w) available in sample ﬁlms.
Water content and thermal stability were analysed based on the
weight loss of ﬁlms using TGA. It can be observed from the thermo-
grams that T3 and T4 sodium salt pure samples contained 1.29% and
1.41% moisture and were stable up to 200 °C, followed by a rapid de-
gradation (Fig. 6a and b). For freshly printed T3 and T4 ﬁlms, the ob-
served weight losses were 1.19% and 1.04%, respectively (Fig. 6). It
was revealed that the solvents that were used in the feed printing so-
lution were evaporated completely during printing and that no solvent
residues were present within the printed ﬁlms. The residual solvent
peaks were not observed in the HPLC chromatograms of T3 and T4
printed ﬁlms (Fig. 1). It was also noticed that the thermal stability of T3
and T4 printed ﬁlms was improved compared with pure forms, which
could be due to the existence of a single phase composite system of
HPMC with T3 or T4 in printed ﬁlms (as evident from DSC thermo-
grams) or due to the presence of large quantities of polymer in printed
ﬁlms which has a relatively higher thermal stability.
The surface and cross-sectional morphologies of both the free ﬁlm
substrate and T3- and T4-printed ﬁlms were observed using SEM
Fig. 5. DSC thermograms depicting: a) T3 (pure), b) T4 (pure) (c) T3 printed ﬁlms and (d) T4 printed ﬁlms.
Fig. 6. TGA thermograms depicting: a) T3 pure, b) T4 Pure, c) T3 printed ﬁlm and d) T4 printed ﬁlms.
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(Fig. 7). In both cases, drug was deposited onto the top surface of the
HPMC substrate and the surface and cross-sectional micrograph of the
substrate ﬁlm revealed its microporous structure (Fig. 7a). In general,
the surface micrographs conﬁrmed the diﬀerences between the sub-
strate and printed ﬁlms but cross-sectional images did not show such
clear evidence. However, it can be seen that marked diﬀerences in the
surfaces of T3 and T4 ﬁlms, with regards to printing pattern, is likely
due to the diﬀerence in volumes of the printing solutions ejected from
the nozzles of the black and colour cartridges. No drug particle residue
was observed in the surface micrographs of T3 and T4 (higher Y-scale
printed dose of T3 and T4 ﬁlms). This could be due to the printing so-
lution being absorbed uniformly into the porous structure of the ﬁlm or
due to the drug being adequately solubilised in the HPMC polymer,
thereby preventing recrystallisation. In such cases, the drug could be
present in the amorphous state on the ﬁlms. It has been well docu-
mented that HPMC forms long chain networks that can prevent the
recrystallisation and enhance the physical stability of drugs (Li and
Taylor, 2018).
4. Conclusion
This study has demonstrated a novel approach of simultaneously
and independently dosing more than one drug (T3 and T4) onto ODFs
using TIJ printing. In particular, a commercial TIJ printer was modiﬁed,
whereby the printer’s sensors were manually activated and a stationary
platform was installed to enable printing onto HPMC substrates. By
containing T3 and T4 ‘inks’ in separate black and colour cartridges,
printing of both drugs onto the same substrate was attained. Dose
modiﬁcation was achieved by changing the length of their respective
print objectives (Y-values), enabling multi-drug combinations con-
taining therapeutic dosages to be successfully produced. The novel
work explored here has the potential to revolutionise the way in which
oral dose combinations are produced, expanding the applications of
ink-jet printing within personalised medicine.
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